MXPA04003828A - Novedosos inhibidores de dipeptidil peptidasa iv (dp-iv) como agentes antiabeticos. - Google Patents
Novedosos inhibidores de dipeptidil peptidasa iv (dp-iv) como agentes antiabeticos.Info
- Publication number
- MXPA04003828A MXPA04003828A MXPA04003828A MXPA04003828A MXPA04003828A MX PA04003828 A MXPA04003828 A MX PA04003828A MX PA04003828 A MXPA04003828 A MX PA04003828A MX PA04003828 A MXPA04003828 A MX PA04003828A MX PA04003828 A MXPA04003828 A MX PA04003828A
- Authority
- MX
- Mexico
- Prior art keywords
- lower alkyl
- optionally substituted
- inhibitors
- phenyl
- independently
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
(ver formula 1)la presente invencion se refiere a una serie de profarmacos de inhibidores de la dipeptidil peptidasa IV (DP-IV) con propiedades mejoradas. Los compuestos pueden usarse ara el tratamiento de cierto numero de enfermedades humanas, incluyendo la tolerancia deteriorada a la glucosa y la diabetes tipo II. Los compuestos de la invencion estan descritos por la formula general (1); en donde R1 es H o CN; R2 se selecciona de CH2R5, CH2CH2R5 y C(R3) (R4) - X2 (CH2)aR5; R3 Y R4 se seleccionan, cada uno independientemente, de H y Me; R5 se selecciona de con (R6) (R7), N(R8) C (=O) R9, N(R8) C (=S) R9, N(R8) y N(R8)R10; R6 Y R7 son cada uno, independientemente, R11(CH2)b o en forma conjunta son -(CH2)2-Z-(CH2)2- O -CH2-O-C6H4-Z-CH2-; R8 es H o Me; R9 se selecciona de R11(CH2)b, R11(CH2)bO y N(R6) (R7); R10 es R11(CH2)b R11 se selecciona de H, alquilo, arilo opcionalmente substituido, aroilo opcionalmente substituido, arilsulfonilo opcionalmente substituido y heteroarilo opcionalmente substituido; R12 se selecciona de H2NCH(R13)CO, H2NCH(R14)CONHCH(R15)CO, C(R16)=C(R17)COR18 Y R19OCO; R13, R14 Y R15 se seleccionan de las cadenas laterales de los aminoacidos proteinicos; R16 se selecciona de H, alquilo inferior (C1 - C6) y fenilo; R17 se selecciona de H y alquilo inferior (C1 - C6); R18 se selecciona de H, alquilo inferior (C1 - C6), OH, O-(alquilo inferior (C1 - C6)) y fenilo; R19 se selecciona de alquilo inferior (C1 - C6), fenilo opcionalmente substituido y R20C(=O)OC(R21)(R22); R20, R21 y R22 se seleccionan, cada uno, independientemente, de H y alquilo inferior (C1 - C6); Z se selecciona de un enlace covalente, -(CH2)C, -O-, -SOd- Y -N(R10)-; X1 es S o CH2; X2 es O, S o Ch2; a es 1, 2 o 3; b es 0 - 3; c es 1 o 2; y d es 0, 1 o 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0125446.5A GB0125446D0 (en) | 2001-10-23 | 2001-10-23 | Novel anti-diabetic agents |
PCT/GB2002/004787 WO2003035067A1 (en) | 2001-10-23 | 2002-10-23 | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04003828A true MXPA04003828A (es) | 2004-07-16 |
Family
ID=9924376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04003828A MXPA04003828A (es) | 2001-10-23 | 2002-10-23 | Novedosos inhibidores de dipeptidil peptidasa iv (dp-iv) como agentes antiabeticos. |
Country Status (18)
Country | Link |
---|---|
US (1) | US7144886B2 (es) |
EP (1) | EP1450794A1 (es) |
JP (1) | JP2005510499A (es) |
KR (1) | KR20040049321A (es) |
CN (1) | CN1329375C (es) |
AR (1) | AR037247A1 (es) |
CA (1) | CA2464256A1 (es) |
GB (1) | GB0125446D0 (es) |
HU (1) | HUP0402403A3 (es) |
IL (1) | IL161192A0 (es) |
MX (1) | MXPA04003828A (es) |
NO (1) | NO20042114L (es) |
NZ (1) | NZ532044A (es) |
PL (1) | PL370149A1 (es) |
RU (1) | RU2004110055A (es) |
UY (1) | UY27511A1 (es) |
WO (1) | WO2003035067A1 (es) |
ZA (1) | ZA200402500B (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1406873B1 (en) | 2001-06-27 | 2007-09-26 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
JP4357293B2 (ja) | 2001-06-27 | 2009-11-04 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
ES2296962T3 (es) | 2001-06-27 | 2008-05-01 | Smithkline Beecham Corporation | Pirrolidinas como inhibidores de dipeptidil peptidasa. |
WO2004099134A2 (en) * | 2003-05-05 | 2004-11-18 | Prosidion Ltd. | Glutaminyl based dp iv-inhibitors |
EP1620091B1 (en) | 2003-05-05 | 2010-03-31 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
DE10348044A1 (de) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
NZ546322A (en) | 2003-10-15 | 2008-11-28 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
DE10348023A1 (de) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
DE10348022A1 (de) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
WO2005049027A2 (en) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
KR20170005163A (ko) | 2003-11-17 | 2017-01-11 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
ES2332920T3 (es) | 2004-01-20 | 2010-02-15 | Novartis Ag | Proceso y formulacion de compresion directa. |
WO2005075436A2 (en) | 2004-02-05 | 2005-08-18 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
AP2007004234A0 (en) * | 2005-04-22 | 2007-12-31 | Alantos Pharm Holding | Dipeptidyl peptidase-IV inhibitors |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
WO2007017423A2 (en) * | 2005-08-11 | 2007-02-15 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising a dpp-iv inhibitor |
GEP20135838B (en) | 2005-09-14 | 2013-06-10 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors usage at diabetes treatment |
CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
NZ571110A (en) | 2006-04-11 | 2011-03-31 | Arena Pharm Inc | Methods of using GPR119 receptor to identify Glucose-dependent Insulinotropic Peptide (GIP) secretagogue compounds useful for increasing bone mass in an individual |
NZ571761A (en) | 2006-04-12 | 2010-07-30 | Probiodrug Ag | 5-phenylimidazoles |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
EP2146210A1 (en) * | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
CA2772488C (en) | 2009-09-11 | 2018-04-17 | Probiodrug Ag | Heterocyclic derivatives as inhibitors of glutaminyl cyclase |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
EP2545047B9 (en) | 2010-03-10 | 2015-06-10 | Probiodrug AG | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
MX2012011631A (es) | 2010-04-06 | 2013-01-18 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo. |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
CA2979033A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
SG11201909046XA (en) | 2017-04-03 | 2019-10-30 | Coherus Biosciences Inc | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3959248A (en) * | 1974-04-03 | 1976-05-25 | Merck & Co., Inc. | Analogs of thyrotropin-releasing hormone |
IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
-
2001
- 2001-10-23 GB GBGB0125446.5A patent/GB0125446D0/en not_active Ceased
-
2002
- 2002-10-22 UY UY27511A patent/UY27511A1/es not_active Application Discontinuation
- 2002-10-22 AR ARP020103995A patent/AR037247A1/es unknown
- 2002-10-23 JP JP2003537634A patent/JP2005510499A/ja not_active Withdrawn
- 2002-10-23 CN CNB028208544A patent/CN1329375C/zh not_active Expired - Fee Related
- 2002-10-23 HU HU0402403A patent/HUP0402403A3/hu unknown
- 2002-10-23 US US10/491,288 patent/US7144886B2/en not_active Expired - Fee Related
- 2002-10-23 IL IL16119202A patent/IL161192A0/xx unknown
- 2002-10-23 MX MXPA04003828A patent/MXPA04003828A/es active IP Right Grant
- 2002-10-23 RU RU2004110055/04A patent/RU2004110055A/ru not_active Application Discontinuation
- 2002-10-23 KR KR10-2004-7005917A patent/KR20040049321A/ko not_active Application Discontinuation
- 2002-10-23 CA CA002464256A patent/CA2464256A1/en not_active Abandoned
- 2002-10-23 PL PL02370149A patent/PL370149A1/xx not_active Application Discontinuation
- 2002-10-23 EP EP02801961A patent/EP1450794A1/en not_active Withdrawn
- 2002-10-23 NZ NZ532044A patent/NZ532044A/en unknown
- 2002-10-23 WO PCT/GB2002/004787 patent/WO2003035067A1/en not_active Application Discontinuation
-
2004
- 2004-03-30 ZA ZA200402500A patent/ZA200402500B/xx unknown
- 2004-05-19 NO NO20042114A patent/NO20042114L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2005510499A (ja) | 2005-04-21 |
IL161192A0 (en) | 2004-08-31 |
CA2464256A1 (en) | 2003-05-01 |
HUP0402403A3 (en) | 2009-05-28 |
KR20040049321A (ko) | 2004-06-11 |
NO20042114L (no) | 2004-07-21 |
ZA200402500B (en) | 2005-01-24 |
RU2004110055A (ru) | 2005-10-20 |
WO2003035067A1 (en) | 2003-05-01 |
GB0125446D0 (en) | 2001-12-12 |
US20050004205A1 (en) | 2005-01-06 |
HUP0402403A2 (hu) | 2005-04-28 |
US7144886B2 (en) | 2006-12-05 |
NZ532044A (en) | 2005-03-24 |
AR037247A1 (es) | 2004-11-03 |
EP1450794A1 (en) | 2004-09-01 |
UY27511A1 (es) | 2003-04-30 |
PL370149A1 (en) | 2005-05-16 |
CN1329375C (zh) | 2007-08-01 |
CN1575171A (zh) | 2005-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04003828A (es) | Novedosos inhibidores de dipeptidil peptidasa iv (dp-iv) como agentes antiabeticos. | |
ATE164837T1 (de) | Acetamidderivate und ihre verwendung als modifizierungsmittel des verhaltens der verdauung | |
NZ511739A (en) | New esters derived from substituted phenyl-cyclohexyl compounds | |
MY131036A (en) | Novel antidiabetic agents | |
TW200519092A (en) | Malonamide derivatives | |
MY116542A (en) | New inhibitors of platelet aggregation. | |
MEP24608A (en) | Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same | |
HUP0300922A2 (hu) | Új vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
IS6257A (is) | Frumuviðloðunartálmar | |
FR2715155B1 (fr) | Inhibiteurs de la monoamine oxydase B et leurs procédés de préparation. | |
DE69425804D1 (en) | Phosphonsäurediesterderivate | |
FR2699918B1 (fr) | Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments. | |
MY133149A (en) | Use of 2,2,6,6 tetraalkylpiperidine-n-oxyl radicals having long alkyl chains as polymerization regulations | |
MXPA05011183A (es) | Sintesis de 2-hidroxi-n, n-dimetil- 3-[[2-[1(r) -(5-metil -2-furanil) propil]amino]-3, 4-dioxo-1 -ciclobuten-1 -il]amino] benzamida. | |
DK0728138T3 (da) | Anthracyclinderivater | |
CY2225B1 (en) | Organic compounds | |
NZ332597A (en) | Alkyloxyamino substituted fluoren-9-ones and their use as protein kinase c inhibitors | |
HUP0301553A2 (hu) | Gyógyászati készítmények és alkalmazásuk neurológiai rendellenességek kezelésére | |
IL153784A0 (en) | Novel n-(2-phenyl-3-aminopropyl) naphthamides | |
MY117938A (en) | (2-morpholinylmethyl) benzamide derivatives | |
TWI263639B (en) | Novel tetrazole derivative | |
DE60324588D1 (de) | Mischungen optischeraufheller | |
GR3025116T3 (en) | Process for the preparation of n-carbonylarylimines useful for the synthesis of therapeutically active taxoids | |
IL107915A (en) | N-substituted azabicycloheptane derivatives and their use as medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |